Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes

Anti-vascular endothelial growth factor (VEGF) therapies have improved clinical outcomes for patients with cancers and retinal vascular diseases. Three anti-VEGF agents, pegaptanib, ranibizumab, and aflibercept, are approved for ophthalmic indications, while bevacizumab is approved to treat colorect...

Descripción completa

Detalles Bibliográficos
Autores principales: MacDonald, Douglas A., Martin, Joel, Muthusamy, Kathir K., Luo, Jiann-Kae, Pyles, Erica, Rafique, Ashique, Huang, Tammy, Potocky, Terra, Liu, Yang, Cao, Jingtai, Bono, Françoise, Delesque, Nathalie, Savi, Pierre, Francis, John, Amirkhosravi, Ali, Meyer, Todd, Romano, Carmelo, Glinka, Meredith, Yancopoulos, George D., Stahl, Neil, Wiegand, Stanley J., Papadopoulos, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2016
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930479/
https://www.ncbi.nlm.nih.gov/pubmed/27234973
http://dx.doi.org/10.1007/s10456-016-9515-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930479/
https://www.ncbi.nlm.nih.gov/pubmed/27234973
http://dx.doi.org/10.1007/s10456-016-9515-8

Ejemplares similares